Could your genes raise your melanoma risk? new study seeks answers
NCT ID NCT00040352
First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 19 times
Summary
This study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide blood or cheek cell samples, and may undergo skin exams and biopsies to help identify risk genes and other factors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify genes and risk factors that help predict melanoma, leading to better screening and prevention strategies for high-risk families.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly benefit participants, and findings may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2002
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All members of families with three or more living melanoma cases in the U.S. are eligible for inclusion in the study if the families are willing to participate.@@@@@@
- Ages
-
4 weeks to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * On referral, persons \>=4 weeks old of any sex, race or ethnicity will be considered for inclusion in the study because of the criteria noted below. * Affected: An individual who meets any of the following criteria will be eligible to participate in this study: * personal medical history of melanoma of an unusual type, pattern, or number diagnosed at any age; or, * known or suspected factor(s) predisposing to melanoma, either genetic or congenital factors (giant congenital nevi, dysplastic nevi, Spitzoid tumors), or unusual demographic features (e.g., very young age of onset, multiple melanomas, previous history of heritable retinoblastoma, Hodgkin's disease, lymphoma, immunodeficiency syndrome, or organ transplant). * Ability of the individual or their parent or legal guardian, to understand, and their willingness to provide informed consent. * Unaffected: An individual who meets any of the following criteria will be eligible to participate in this study: * family medical history of melanoma of an unusual type, pattern, or number; or, * known or suspected factor(s) predisposing to melanoma, either genetic or congenital factors (giant congenital nevi, dysplastic nevi. Spitzoid tumors), or unusual demographic features (e.g., very young age of onset, multiple melanomas, previous history of heritable retinoblastoma, Hodgkin's disease, lymphoma, immunodeficiency syndrome, or organ transplant). * Ability of the individual or their parent, or legal guardian to understand, and their willingness to provide informed consent. * Personal and family medical history must be verified through questionnaires, interviews, and review of pathology slides and medical records. EXCLUSION CRITERIA: * Referred individuals and families for whom reported diagnoses cannot be verified; * Inability to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dysplastic nevus syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cancer Institute (NCI)
RECRUITINGBethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Blood test could spot Melanoma's BRAF mutation
- Can a CXCR1/2 blocker boost radiation against cancer that spreads to the brain lining?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can tumor DNA and immune cells reveal why some cancers resist immunotherapy?
- Can a Two-Drug immune combo shrink melanoma tumors?